275 related articles for article (PubMed ID: 26678060)
1. IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
Galluzzo M; Boca AN; Botti E; Potenza C; Malara G; Malagoli P; Vesa S; Chimenti S; Buzoianu AD; Talamonti M; Costanzo A
Dermatology; 2016; 232(2):230-6. PubMed ID: 26678060
[TBL] [Abstract][Full Text] [Related]
2. Genetic variations in IL6 and IL12B decreasing the risk for psoriasis.
Boca AN; Talamonti M; Galluzzo M; Botti E; Vesa SC; Chimenti S; Buzoianu AD; Costanzo A
Immunol Lett; 2013; 156(1-2):127-31. PubMed ID: 24140476
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
[TBL] [Abstract][Full Text] [Related]
4. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
[TBL] [Abstract][Full Text] [Related]
5. Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus.
Eirís N; González-Lara L; Santos-Juanes J; Queiro R; Coto E; Coto-Segura P
J Dermatol Sci; 2014 Sep; 75(3):167-72. PubMed ID: 24957500
[TBL] [Abstract][Full Text] [Related]
6. Association of IL12B risk haplotype and lack of interaction with HLA-Cw6 among the psoriasis patients in India.
Chandra A; Senapati S; Ghosh S; Chatterjee G; Chatterjee R
J Hum Genet; 2017 Mar; 62(3):389-395. PubMed ID: 27829679
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.
Talamonti M; Botti E; Galluzzo M; Teoli M; Spallone G; Bavetta M; Chimenti S; Costanzo A
Br J Dermatol; 2013 Aug; 169(2):458-63. PubMed ID: 23521149
[TBL] [Abstract][Full Text] [Related]
8. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
[TBL] [Abstract][Full Text] [Related]
9. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.
Talamonti M; Galluzzo M; van den Reek JM; de Jong EM; Lambert JLW; Malagoli P; Bianchi L; Costanzo A
Br J Dermatol; 2017 Aug; 177(2):489-496. PubMed ID: 28207934
[TBL] [Abstract][Full Text] [Related]
10. Association between psoriasis and polymorphisms in the TNF, IL12B, and IL23R genes in Spanish patients.
Cabaleiro T; Román M; Gallo E; Ochoa D; Tudelilla F; Talegón M; Prieto-Pérez R; García-Díez A; Daudén E; Abad-Santos F
Eur J Dermatol; 2013; 23(5):640-5. PubMed ID: 24135300
[TBL] [Abstract][Full Text] [Related]
11. IL12B, IL23A, IL23R and HLA-C*06 genetic variants in psoriasis susceptibility and response to treatment.
Bojko A; Ostasz R; Białecka M; Klimowicz A; Malinowski D; Budawski R; Bojko P; Droździk M; Kurzawski M
Hum Immunol; 2018 Apr; 79(4):213-217. PubMed ID: 29454820
[TBL] [Abstract][Full Text] [Related]
12. Resequencing of the IL12B gene in psoriasis patients with the rs6887695/rs3212227 risk genotypes.
Eiris N; Santos-Juanes J; Coto-Segura P; Gómez J; Alvarez V; Morales B; Queiro R; Díaz M; Corao AI; López-Corte K; Coto E
Cytokine; 2012 Oct; 60(1):27-9. PubMed ID: 22739501
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
[TBL] [Abstract][Full Text] [Related]
14. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up.
Talamonti M; Galluzzo M; Chimenti S; Costanzo A
J Am Acad Dermatol; 2016 Feb; 74(2):374-5. PubMed ID: 26775778
[No Abstract] [Full Text] [Related]
15. Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab.
Raposo I; Carvalho C; Bettencourt A; Da Silva BM; Leite L; Selores M; Torres T
Eur J Dermatol; 2017 Oct; 27(5):528-530. PubMed ID: 29084639
[No Abstract] [Full Text] [Related]
16. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis.
Nair RP; Ruether A; Stuart PE; Jenisch S; Tejasvi T; Hiremagalore R; Schreiber S; Kabelitz D; Lim HW; Voorhees JJ; Christophers E; Elder JT; Weichenthal M
J Invest Dermatol; 2008 Jul; 128(7):1653-61. PubMed ID: 18219280
[TBL] [Abstract][Full Text] [Related]
17. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
Dand N; Duckworth M; Baudry D; Russell A; Curtis CJ; Lee SH; Evans I; Mason KJ; Alsharqi A; Becher G; Burden AD; Goodwin RG; McKenna K; Murphy R; Perera GK; Rotarescu R; Wahie S; Wright A; Reynolds NJ; Warren RB; Griffiths CEM; Smith CH; Simpson MA; Barker JN; ; ;
J Allergy Clin Immunol; 2019 Jun; 143(6):2120-2130. PubMed ID: 30578879
[TBL] [Abstract][Full Text] [Related]
18. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.
Cargill M; Schrodi SJ; Chang M; Garcia VE; Brandon R; Callis KP; Matsunami N; Ardlie KG; Civello D; Catanese JJ; Leong DU; Panko JM; McAllister LB; Hansen CB; Papenfuss J; Prescott SM; White TJ; Leppert MF; Krueger GG; Begovich AB
Am J Hum Genet; 2007 Feb; 80(2):273-90. PubMed ID: 17236132
[TBL] [Abstract][Full Text] [Related]
19. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis.
Filer C; Ho P; Smith RL; Griffiths C; Young HS; Worthington J; Bruce IN; Barton A
Arthritis Rheum; 2008 Dec; 58(12):3705-9. PubMed ID: 19035472
[TBL] [Abstract][Full Text] [Related]
20. HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.
Li K; Huang CC; Randazzo B; Li S; Szapary P; Curran M; Campbell K; Brodmerkel C
J Invest Dermatol; 2016 Dec; 136(12):2364-2371. PubMed ID: 27476722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
